Key facts
- What it is: Lanreotide is a long-acting somatostatin analog used in acromegaly and selected gastroenteropancreatic neuroendocrine tumors.
- Evidence: Strong human evidence for acromegaly and selected neuroendocrine tumors.
- Status: FDA-approved somatostatin analog.
- Main caution: Gallstones, diarrhea or abdominal symptoms, glucose changes, slowed heart rate, and thyroid effects can occur.
- Sources: 5 PubMed-indexed papers linked below.
What is Lanreotide?
Lanreotide is a long-acting somatostatin analog used in acromegaly and selected gastroenteropancreatic neuroendocrine tumors. It is delivered as a deep subcutaneous depot. Its role overlaps with octreotide but the formulations, labeled indications, and trial programs are not identical.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For Lanreotide, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does Lanreotide work?
Binding to somatostatin receptors suppresses growth hormone and hormone secretion from susceptible neuroendocrine cells. In receptor-positive tumors, chronic signaling can slow growth even when dramatic shrinkage is uncommon.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on Lanreotide show?
CLARINET showed longer progression-free survival with lanreotide than placebo in metastatic enteropancreatic neuroendocrine tumors. Acromegaly studies support biochemical control, while comparative and switch studies explore patients inadequately controlled on one analog.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Strong human evidence for acromegaly and selected neuroendocrine tumors. CLARINET enrolled a defined, mostly stable disease population. Results should not be generalized to every tumor grade, primary site, receptor pattern, or rapidly progressive cancer.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is Lanreotide approved or available?
FDA-approved somatostatin analog. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
Lanreotide safety, risks, and evidence gaps
Gallstones, diarrhea or abdominal symptoms, glucose changes, slowed heart rate, and thyroid effects can occur. Monitoring reflects both the drug and the underlying endocrine disease.
CLARINET enrolled a defined, mostly stable disease population. Results should not be generalized to every tumor grade, primary site, receptor pattern, or rapidly progressive cancer.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is Lanreotide?
Lanreotide is a long-acting somatostatin analog used in acromegaly and selected gastroenteropancreatic neuroendocrine tumors. It is delivered as a deep subcutaneous depot. Its role overlaps with octreotide but the formulations, labeled indications, and trial programs are not identical.
How does Lanreotide work?
Binding to somatostatin receptors suppresses growth hormone and hormone secretion from susceptible neuroendocrine cells. In receptor-positive tumors, chronic signaling can slow growth even when dramatic shrinkage is uncommon.
Is Lanreotide FDA-approved?
FDA-approved somatostatin analog. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on Lanreotide show?
CLARINET showed longer progression-free survival with lanreotide than placebo in metastatic enteropancreatic neuroendocrine tumors. Acromegaly studies support biochemical control, while comparative and switch studies explore patients inadequately controlled on one analog.
What are the main risks of Lanreotide?
Gallstones, diarrhea or abdominal symptoms, glucose changes, slowed heart rate, and thyroid effects can occur. Monitoring reflects both the drug and the underlying endocrine disease.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. — PubMed 25014687 (2014)
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. — PubMed 10774879 (2000)
- Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. — PubMed 11504080 (2001)
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. — PubMed 15151956 (2004)
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. — PubMed 25260838 (2014)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.